Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the “cancer-immunity cycle” in the pan-cancer setting in order to understand the immune landscape of metastati...

Full description

Bibliographic Details
Main Authors: Shumei Kato, Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez Eskander, Aaron Goodman, Suzanna Lee, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Felicia L. Lenzo, Carl Morrison, Razelle Kurzrock
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
immunotherapy
biomarker
resistance
cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1708065

Internet

http://dx.doi.org/10.1080/2162402X.2019.1708065

Similar Items